skip to Main Content

Inhibition of PAK1 Suppresses Pancreatic Cancer by Stimulation of Anti-Tumour Immunity Through Down-Regulation of PD-L1

Inhibition of PAK1 Suppresses Pancreatic Cancer by Stimulation of Anti-Tumour Immunity Through Down-Regulation of PD-L1
Immunotherapies have not yielded significant clinical benefits for pancreatic ductal adenocarcinoma (PDA) because of the existence of an immunosuppressive tumour microenvironment (TME) characterised by a desmoplastic stroma containing infiltrated immune cells and activated pancreatic stellate cells (PSCs). {/subhead]

This study aims to investigate the involvement of PAK1 in anti-tumour immunity. Read more . . .  


Back To Top